Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation.
DNA repair
PARP inhibitor
gemcitabine
pancreatic cancer
proton therapy
radiotherapy
transcriptome
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Jan 2021
30 Jan 2021
Historique:
received:
30
12
2020
revised:
26
01
2021
accepted:
27
01
2021
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
epublish
Résumé
Over the past few years, studies have focused on the development of targeted radiosensitizers such as poly(ADP-ribose) polymerase inhibitors. We performed an in vivo study and a whole-transcriptome analysis to determine whether PARP inhibition enhanced gemcitabine-based chemoradiosensitization of pancreatic cancer xenografts, combined with either proton or photon irradiation. NMRI mice bearing MIA PaCa-2 xenografts were treated with olaparib and/or gemcitabine and irradiated with 10 Gy photon or proton. First, a significant growth inhibition was obtained after 10 Gy proton irradiation compared to 10 Gy photon irradiation (
Identifiants
pubmed: 33573176
pii: cancers13030527
doi: 10.3390/cancers13030527
pmc: PMC7866541
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ligue Contre le Cancer
ID : CCIRGE-BFC
Références
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142778
Clin Oncol (R Coll Radiol). 2014 Sep;26(9):560-8
pubmed: 25001636
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Radiat Res. 2015 Jan;183(1):114-23
pubmed: 25564718
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Neoplasia. 2009 May;11(5):418-25
pubmed: 19412426
EMBO Mol Med. 2017 Feb;9(2):137-153
pubmed: 28028012
Neoplasia. 2015 Oct;17(10):757-66
pubmed: 26585231
J Gastrointest Oncol. 2020 Feb;11(1):166-175
pubmed: 32175120
PLoS One. 2016 Dec 29;11(12):e0167272
pubmed: 28033382
Transl Cancer Res. 2017 Jul;6(Suppl 5):S900-S913
pubmed: 30733931
Acta Biochim Biophys Sin (Shanghai). 2019 Nov 18;51(11):1142-1147
pubmed: 31650163
Mol Cancer Res. 2018 Apr;16(4):587-598
pubmed: 29378907
Cell Death Dis. 2012 Dec 06;3:e441
pubmed: 23222511
Acta Oncol. 2013 Apr;52(3):498-505
pubmed: 23477361
Oncol Lett. 2019 Dec;18(6):6801-6806
pubmed: 31807188
EBioMedicine. 2019 Feb;40:375-381
pubmed: 30635165
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cancer Sci. 2012 Jun;103(6):1045-50
pubmed: 22404155
Cancers (Basel). 2018 Jan 03;10(1):
pubmed: 29301364
Immunol Lett. 2015 Nov;168(1):111-9
pubmed: 26450014
Radiat Res. 2010 Aug;174(2):238-50
pubmed: 20681790
Phys Med Biol. 2014 Nov 21;59(22):R419-72
pubmed: 25361443
Biochem Biophys Res Commun. 2016 Sep 9;478(1):234-240
pubmed: 27425251
Cancers (Basel). 2015 Feb 12;7(1):353-81
pubmed: 25686476
Int J Mol Sci. 2018 Nov 28;19(12):
pubmed: 30487462
Pharmacogenet Genomics. 2014 Nov;24(11):564-74
pubmed: 25162786
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):86-94
pubmed: 26452569
Clin Cancer Res. 2013 Aug 15;19(16):4412-21
pubmed: 23804422
Biochem Biophys Res Commun. 2020 May 21;526(1):128-134
pubmed: 32199616
Mol Aspects Med. 2013 Dec;34(6):1217-56
pubmed: 23370117
Transl Cancer Res. 2018 Mar;7(Suppl 2):S243-S252
pubmed: 30148073
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):59-61
pubmed: 27084628
Med Phys. 2019 May;46(5):2356-2362
pubmed: 30924942
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):776-784
pubmed: 29413288
Cancer Res. 2017 Aug 1;77(15):3965-3981
pubmed: 28701486
Nat Rev Mol Cell Biol. 2016 Dec;17(12):756-770
pubmed: 27780979
Clin Cancer Res. 2014 Oct 1;20(19):5085-96
pubmed: 25117293
Med Phys. 2018 Jan;45(1):470-478
pubmed: 29178161
Mol Cancer Ther. 2006 Mar;5(3):564-74
pubmed: 16546970